Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions

Shamema Nasrin, Christy J.W. Watson, Yadira X Perez-Paramo*, Philip Lazarus

Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.

* Current affiliation: Genentech, Inc., South San Francisco, California, USA 94080
Running Title: Cannabinoid metabolites as CYP450 inhibitors

Corresponding author: Philip Lazarus, Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA. Email: phil.lazarus@wsu.edu

Number of text pages:

Number of tables: 4
Number of figures: 3
Number of supplemental tables: 2
Number of supplemental figures: 2
Number of references: 50

Number of words:

Abstract: 248 words
Introduction: 801 words
Discussion: 1,767 words

Abbreviations: Area under the curve, AUC; bicinchoninic acid, BCA; cannabidiol, CBD; cannabinol, CBN; cytochrome P450, CYP; drug-drug interaction, DDI; human embryonic kidney, HEK; human liver microsomes, HLM; half-maximal inhibitory concentration, IC50; inhibitory constant, Ki; liquid chromatography-tandem mass
spectrometry, LC-MS/MS; multiple reaction monitoring, MRM; β-nicotinamide adenine dinucleotide phosphate, NADP; time-dependent inhibition, TDI; (−)-trans-Δ⁹-tetrahydrocannabinol, THC; ultra-high-performance liquid chromatography, UPLC; 11-hydroxy-Δ⁹-tetrahydrocannabinol, 11-OH-THC; 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol, THC-COOH; 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol glucuronide, THC-COO-Gluc.
Abstract

The legalization of cannabis in many parts of the United States and other countries has led to a need for a more comprehensive understanding of cannabis constituents and their potential for drug-drug interactions. While (+)-trans-Δ⁹-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN) are the most abundant cannabinoids present in cannabis, THC metabolites are found in plasma at higher concentrations and for a longer duration than that of the parent cannabinoids. To understand the potential for drug-drug interactions, the inhibition potential of major cannabinoids and their metabolites on major hepatic cytochrome P450 (CYP) enzymes was examined. In vitro assays with CYP-overexpressing cell microsomes demonstrated that the major THC metabolites 11-hydroxy-Δ⁹-tetrahydrocannabinol (11-OH-THC) and 11-COO-Δ⁹-THC-glucuronide (THC-COO-Gluc) competitively inhibited several major CYP enzymes, including CYP2B6, CYP2C9, and CYP2D6 (apparent $K_{i,u}$ values = 0.086 ± 0.066 µM and 0.90 ± 0.54 µM, 0.057 ± 0.044 µM and 2.1± 0.81 µM, 0.15 ± 0.067 µM and 2.3 ± 0.54 µM, respectively). 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol (THC-COOH) exhibited no inhibitory activity against any CYP450 tested. THC competitively inhibited CYPs 1A2, 2B6, 2C9, and 2D6, CBD competitively inhibited CYPs 3A4, 2B6, 2C9, 2D6, and 2E1, and CBN competitively inhibited CYPs 2B6, 2C9, and 2E1. THC and CBD showed mixed-type inhibition for CYP2C19 and CYP1A2, respectively. These data suggest that cannabinoids and major THC metabolites are able to inhibit the activities of multiple CYP enzymes, and basic static modelling of these data suggest the possibility of pharmacokinetic interactions between these cannabinoids and xenobiotics extensively metabolized by CYP2B6, CYP2C9 and CYP2D6.
Significance Statement

Major cannabinoids and their metabolites found in the plasma of cannabis users inhibit several CYP enzymes, including CYP2B6, CYP2C9, and CYP2D6. This study is the first to show the inhibition potential of the most abundant plasma cannabinoid metabolite, THC-COO-Gluc, and suggests that circulating metabolites of cannabinoids play an essential role in CYP450 enzyme inhibition as well as drug-drug interactions.
Introduction

Cannabis and cannabis-derived substances are the most widely consumed psychopharmaceuticals in the world (Atakan, 2012). The legal and ethical implications of their use continue to be the subject of intense global debate due to potential medical applications of cannabis-derived products and the progressive legalization of its use as a recreational drug. Modern clinical applications include treatment of multiple sclerosis, epilepsy, neuropathic pain, arthritis, nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, depression, anxiety disorders, sleep disorders, psychosis, glaucoma, and Tourette syndrome, among others (Renata et al., 2017). However, concurrent usage of cannabis products (both recreational and medicinal) with conventional medications, non-prescription remedies, and other psychoactive substances can often lead to substance-use disorders (NIDA report, July 2020), suggesting that more information is needed to fully understand the effects of cannabis as a psychopharmaceutical (Weinberger et al., 2016).

More than 500 phytochemicals have been detected in commercial strains of the Cannabis sativa plant, with Δ⁹-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN) being the three main active constituents (Aizpurua-Olaizola et al., 2016). THC is the most well-described psychoactive constituent and interacts with the CB1 receptor and the complex network of neurological transmitters to induce psychopharmacological effects (Pertwee, 2008). Guidelines from the Food and Drug Administration classify any cannabis-derived substance that contains more than 0.3% THC as a Schedule I controlled substance, while products with less than 0.3% THC are
classified as the agricultural product, hemp. CBD does not bind to the CB1 receptor and does not produce the same psychoactive responses. In fact, when CBD and THC are administered simultaneously, CBD appears to block some of the effects of THC by acting as an antagonist at the cannabinoid receptors (Pertwee, 2008). CBD administered without THC has been shown to reduce subjective anxiety in both animals and humans and is thought to produce a positive effect on conditions such as inflammation, diabetes, cancer, and neurodegenerative diseases (Maroon and Bost, 2018). CBN is only weakly psychoactive and appears to be formed primarily from the degradation of THC within the Cannabis plant itself (Russo and Marcu, 2017).

Upon consumption, the first step of metabolism of THC is hydroxylation mediated by CYP2C9, resulting in the active metabolite, 11-hydroxy-Δ⁹-tetrahydrocannabinol (11-OH-THC; see Figure 1). Although 11-OH-THC predominates as the first oxidation product, small amounts of 8β-OH-THC and 8α-OH-THC are also formed (Matsunaga et al., 1995). Much lower plasma 11-OH-THC concentrations (ca. 10% of THC concentrations) are found after cannabis smoking than after oral administration (Wall et al., 1983). Further hydroxylation by CYP2C9 leads to the inactive carboxylic acid derivative, 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol (THC-COOH), which does not interact with the CB1 receptor. THC-COOH is a substrate for UGT enzymes which add a glucuronide moiety to form 11-COO-Δ⁹-tetrahydrocannabinol-glucuronide (THC-COO-Gluc), the major end product of THC biotransformation in most species including humans (Huestis, 2007). CBN is the nonenzymatic oxidation byproduct of THC and is most commonly found after prolonged storage, especially at higher temperatures.
CBD follows the same metabolic scheme as THC, with hydroxylation on the homologous 7 carbon via CYP2C19 and CYP3A4 to form 7-OH-CBD and CBD-COOH, followed by glucuronidation to form CBD-COO-glucuronide. However, 7-OH-CBD is only a minor biotransformation product in the plasma after cannabis inhalation, with unchanged CBD and, to a lesser extent, glucuronidated CBD, as the main excretion products in urine (Harvey and Mechoulam, 1990; Huestis, 2007).

Cannabinoids are highly lipophilic, eventually concentrating in adipose tissue, liver, lung, and spleen, with slow release back into the bloodstream. This leads to varying plasma concentrations of active and inactive metabolites that persist in the bloodstream for a much wider timeframe than that of THC. Plasma concentrations of THC and its active metabolite, 11-OH-THC, change rapidly over time and vary widely depending on the mode of consumption and expertise of the user (occasional vs frequent user, depth of inhalation, puff duration, and breath-hold) (Sharma et al., 2012). In contrast, the inactive metabolites THC-COOH and THC-COO-Gluc are present at relatively high levels regardless of the mode of consumption. Inhaled and ingested THC produces the same approximate level of THC-COOH. Once reaching maximal levels at approximately 80 minutes and 2 hours post-inhalation, the level of THC-COOH and its glucuronide, THC-COO-Gluc, remain very stable in the bloodstream over many days, whereas THC is rapidly metabolized and cleared from the circulation (Huestis, 2007; Schwöpe et al., 2011; Sharma et al., 2012).

While previous studies have shown that the cannabinoids THC, CBD, and CBN can inhibit several major hepatic CYPs (Yamaori et al., 2010; Yamaori et al., 2011a;
Yamaori et al., 2011b; Yamaori et al., 2011c; Jiang et al., 2013; Cox et al., 2019), no studies have focused on the inhibitory potential of the major abundant metabolites of THC. The present study is the first to perform a comprehensive analysis of the inhibition activities of major cannabinoids and THC metabolites against major human hepatic CYP450 enzymes.
Material and methods

Chemicals and Reagents

The purchase of THC, 11-OH-THC, THC-COOH, THC-COO-Gluc, CBD, and CBN was approved by the Drug Enforcement Administration and were obtained from Cayman Chemicals (Ann Arbor, MI) or Sigma-Aldrich (St. Louis, MO). The internal standards (IS) D₃-THC and D₃-THC-COO-Gluc, were purchased from Sigma-Aldrich. Pooled human liver microsomes (HLM; n=50 subjects, mixed gender) were obtained from Sekisui Xenotech, LLC (Lenexa, Kansas). NADPH-regenerating system (1.3 mM NADP, 3.3 mM glucose 6-phosphate, and 0.4 U/mL glucose 6-phosphate dehydrogenase) was obtained from Corning (Bedford, MA). CYP450 probe substrates (phenacetin, bupropion, (S)-bufuralol hydrochloride, amodiaquine, diclofenac, omeprazole, dextromethorphan, chlorzoxazone, and midazolam), their corresponding metabolite standards (acetaminophen, hydroxybupropion, hydroxybupropion-D₆, 4-hydroxydiclofenac, 4-hydroxydiclofenac-¹³C₆, 5-hydroxyomeprazole, dextrorphan, dextrorphan-D₃, 6-hydroxychlorzoxazone, and 1-hydroxymidazolam), along with probe inhibitors (furafylline, clopidogrel, montelukast, sulfaphenazole, tranilcyprine, quinidine, chlomethiazole, and ketoconazole) were all purchased from Sigma-Aldrich. (-) Warfarin and efavirenz were purchased from Cayman Chemicals (Ann Arbor, MI). LC-MS grade methanol, acetonitrile, and formic acid, as well as ultra-low-binding microcentrifuge tubes, were obtained from Fisher Scientific (Waltham, MA). All other chemicals and reagents were of analytical grade or the highest grade that was commercially available. Dulbecco’s Modified Eagles Medium, Dulbecco’s phosphate-buffered saline, fetal bovine serum, and geneticin (G418) were purchased from Gibco (Grand Island, NY). BCA protein assays were purchased from Pierce (Rockford, Illinois, USA).
In vitro CYP450 activity assays and metabolite detection

HEK293 cells individually overexpressing V5-tagged CYP isoforms 1A2, 3A4, 2B6, 2C8, 2C9, 2C19, 2D6, and 2E1 were developed and described previously (Peterson et al., 2017b). Microsomal membrane fractions of CYP-overexpressing cell lines were prepared by differential centrifugation as previously described, with protein concentrations estimated using the BCA assay as per the manufacturer’s recommendations (Dellinger et al., 2006; Peterson et al., 2017b; Peterson et al., 2017a). An initial screen of the inhibition potential of individual cannabinoids and their metabolites against major CYPs (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4) were determined using microsomes (20 – 50 µg) from CYP450-overexpressing HEK293 cell lines in reactions containing either 1 µM or 10 µM of cannabinoid/THC metabolite, specific probe substrate (see Supplementary Table 1), 100 mM potassium phosphate buffer (pH 7.4) and magnesium chloride (3 mM) in a final reaction volume of 30 µL. The probe substrates were used at concentrations near or just below their respective Michaelis–Menten constant values (K_m) to minimize any unwanted interactions among P450 probe substrates (Supplemental Table 1). As THC exhibits extensive non-specific binding (70-90%) to protein and labware (Garrett and Hunt, 1974), microsomal incubation conditions were optimized to prevent underestimation of inhibitory potency (IC_{50} or K_i). To reduce non-specific binding and adsorption to labware, low-binding 1.6 mL microcentrifuge tubes were used for all reactions. Assays were pre-incubated for 5 min at 37°C, initiated by the addition of NADPH-regenerating system, and incubated for 5 - 30 min (Supplemental Table 1) at 37°C. Reactions were terminated by the addition of 30 µL of ice-cold stop solution (acetonitrile/methanol; 1:1). Samples were mixed on a vortex mixer and centrifuged at 17,000 x g for 15 min. The supernatant (~50 µL) was transferred to an ultra-performance liquid chromatograph (UPLC) sample vial, and the specific probe substrate metabolite was detected using a UPLC (Waters Acquity; Waters Corp, Milford, MA) coupled to a triple-quadrupole mass spectrometer (Waters Xevo TQD; Waters Corp) by multiple
reaction monitoring (MRM) analysis (Supplemental Table 1). As a positive control for every inhibition experiment, 1 µM and 10 µM probe inhibitors (see Supplemental Table 1) were added instead of the cannabinoid compounds. As a negative control, only vehicle (3% methanol) was added (without inhibitor) to the reaction. Probe substrate without any inhibitor was used as a positive control for activity. All analyses were performed in three independent experiments. Incubation conditions were optimized by incubations of the individual probe substrates with microsomes from overexpressing cell lines at 10, 20, 30, 50 µg microsomal protein for different times (5, 15, 25, and 30 min). Remaining substrate and formed metabolite peaks for each reaction were analyzed and conditions were chosen according to the following criteria: (1) metabolite formation was linear with time, and enzyme concentration, (2) substrate consumption was no more than 20% of the initial amount, and (3) all metabolites could be easily detected by LC–MS/MS methods.

For UPLC-MS/MS, the mobile phase consisted of solvent A (0.1% formic acid in water) and solvent B (100% methanol). Samples (2-5 µL) were injected onto an Acquity UPLC column (BEH C18, 1.7 µM, 2.1 X 100 mm: Waters Corp). A 6-minute gradient elution was used, as follows: 2 min at 95% A:5% B followed by a linear gradient for 2 min to 5% A:95% B, 1 min at 5% A:95% B and re-equilibration for 1 min at 95% A:5% B. The flow rate was 0.4 mL/min, and the column temperature was 40°C.

**Determination of IC_{50} and K_i values**

For those cannabinoids/THC metabolites that exhibited a >50% decrease in relative CYP activity for any given probe substrate at ≤10 µM, IC_{50} determinations were performed in both microsomes from HEK293 CYP450-overexpressing cell lines (described above) and in HLM using multiple concentrations (ranging between 0.5 -100 µM) of cannabinoid/metabolite in
incubations as described above, with all determinations performed for three independent experiments with 3 replicates per experiment.

To identify possible metabolism-dependent inhibition of the potential enzymes, IC\textsubscript{50} shift studies (Parkinson et al., 2011) were performed using HEK-overexpressing cell lines. Reactions containing the test cannabinoid or THC metabolite (inhibitor) but no probe substrate were incubated with or without NADPH at 37°C for 30 min. After this 30 min preincubation, probe substrate was added to the incubation mixture and incubated at 37°C for up to 30 min (Supplementary Table 1). Peak areas corresponding to the probe metabolite were determined and the percentage of control activity was calculated by comparing the peak area in incubations containing the inhibitors to incubations containing only the vehicle control. The differences between the IC\textsubscript{50} values obtained with or without the NADPH preincubation period were compared and the fold-IC\textsubscript{50} shift was determined. The cannabinoid/THC metabolite with a fold-IC\textsubscript{50} shift of ≥1.5 was considered a time-dependent inhibitor as recommended by FDA guidelines.

IC\textsubscript{50} data were used as a guide to generate appropriate probe substrate and test inhibitor concentrations for the determination of the \textit{K}_i values for each isoform. The CYP enzyme-specific probe substrate concentrations used were 1 to 25 μM phenacetin for CYP1A2, 12.5 to 100 μM bupropion for CYP2B6, 2.5 to 30 μM diclofenac for CYP2C9, 0.5 to 5 μM omeprazole for CYP2C19, 1 to 10 μM dextromethorphan for CYP2D6, 12.5 to 100 μM chlorzoxazone for CYP2E1, and 1 to 25 μM midazolam for CYP3A4.

Data were exported and analyzed using an Excel spreadsheet (Microsoft, USA). The amount of metabolite formed at each concentration relative to the control (percent relative activity) of specific enzyme in the presence and absence of probe inhibitor or test compound was calculated as:
% Relative activity = (test - test blank) / control - control blank) × 100%.

Percent Inhibition = Rate without inhibitor - rate with inhibitor / rate without inhibitor × 100

The IC<sub>50</sub> values were calculated by plotting the percent inhibition of CYP enzyme activities versus log concentration of the test inhibitors using GraphPad Prism 7.04 software (GraphPad Software Inc., San Diego, CA).

To calculate K<sub>i</sub> values, inhibition data were fit to different models of enzyme inhibition (competitive, uncompetitive, or noncompetitive) by nonlinear least-squares regression analysis using the GraphPad Prism 7.04 software. K<sub>i</sub> values were calculated with the use of nonlinear regression according to the equations:

\[ v = \frac{V_{\text{max}} S}{K_m (1+I/K_i)+S} \] for competitive inhibition,

\[ v = \frac{V_{\text{max}} S}{K_m + S (1+I/K_i)} \] for mixed inhibition

where I is compound concentration, K<sub>i</sub> is the inhibition constant, S is the substrate concentration, and K<sub>m</sub> is the substrate concentration at half of the maximum velocity (V<sub>max</sub>) of the reaction (Cornish-Bowden, 1974).

**Bound vs unbound cannabinoid determinations**

Cannabinoid binding to proteins and tube walls in the incubation mixture (f<sub>u,inc</sub>) was measured using the tube adsorption method as described previously (Isoherranen et al., 2004; Patilea-Vrana and Unadkat, 2019). Briefly, in separate incubations, 50 µL of 50 µM THC, 11-OH-THC, THC-COO-Gluc, CBD or CBN was added to each of two 0.6 mL low-binding centrifuge tubes containing buffer without protein, two 0.6 mL low-binding centrifuge tubes containing buffer with HLM (25 µg), or two 0.6 mL low-binding centrifuge tubes containing buffer.
with HEK293 microsomal protein (30 µg). This was performed for each cannabinoid separately. Mixtures were incubated for 30 min at 37°C with occasional shaking. For one tube of the three incubation conditions (buffer alone, buffer + HLM, and buffer + HEK293 microsomes), ice-cold acetonitrile (100 µL) containing D$_3$-labelled cannabinoid IS was added (subgroup A). For the other tube of each condition, the entire 50 µL mixture was removed and added to a fresh tube which contained 100 µl ice-cold acetonitrile with D$_3$-labelled cannabinoid IS (subgroup B). Samples were processed for UPLC-MS/MS as described below for the in vitro assay experiments. All analyses were performed in three independent experiments with four replicates per experiment.

The separation and detection of individual cannabinoids was achieved using the same ACQUITY XEVO TQD (Waters Corporation, Millford, MA) chromatographic system described above, using a Waters BEH C$_{18}$ column 1.7 mm, 2.1 x 50 mm, at 40°C. UPLC-MS/MS was performed with a gradient elution using mobile phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile) at a flow rate of 0.4 mL/min under the following conditions: 5% B for 1.0 min, increasing to 95% B from 1.0 to 4.0 min, 95% B held for 2 min, followed by a return to initial conditions for 1.5 min, for a total time of 7.5 min. Detection of cannabinoids was performed in MRM ES+ mode using the following mass transitions: $m/z$ 315.1 → 193.2 for THC, $m/z$ 331.3 → 313.1 for 11-OH-THC, $m/z$ 315.2 → 181.1 for CBD, $m/z$ 311.2 → 223.0 for CBN, $m/z$ 521.2 → 345.0 for THC-COO-Gluc. Cone voltages (V) of 40, 40, 50, and 30, respectively, and collision energies (eV) of 25, 18, 20, and 27, respectively, were used for THC, 11-OH-THC, CBD, CBN, THC-COO-Gluc. Due to the non-availability of deuterated CBD or CBN at the time of this study, and due to the similar molecular weights and UPLC retention times between these cannabinoids, THC-D$_3$ was used as the IS for the quantification of THC, CBD and CBN; 11-OH-THC-D$_3$ was used to quantify 11-OH-THC while THC-COO-Gluc-D$_3$ was used to quantify THC-COO-Gluc. The internal standards were detected using the same cone voltages and collision energies as their respective standards, with the following mass transitions
transitions: \( m/z \) 318.1 \( \rightarrow \) 196.2 for THC-D\(_3\), \( m/z \) 334.3 \( \rightarrow \) 316.1 for 11-OH-THC-D\(_3\), and \( m/z \) 523.2 \( \rightarrow \) 348.0 for THC-COO-Gluc-D\(_3\).

The unbound fraction of cannabinoid in incubations with either HLM or HEK293 microsomes \( (f_{u,inc}) \) was calculated using the following equation:

\[
f_{u,inc} = \frac{CB_B}{CB_A - CB_B} \cdot \left( \frac{CP_A - CP_B}{CP_B} \right)
\]

where \( CB_A \) is the total (adsorbed and unadsorbed) test compound in buffer only, and \( CB_B \) is unadsorbed test compound in buffer. So, \( CB_A - CB_B \) is the test compound adsorbed to the tube wall, and \( CB_B / CB_A - CB_B \) is the ratio of unbound test compound relative to the test compound adsorbed to the wall. \( CP_A \) is the total (adsorbed and unadsorbed) test compound in the incubation mixture, and \( CP_B \) is unbound test compound in presence of protein source (incubation mixture). \( CP_A - CP_B \) is the test compound adsorbed to the tube wall when mixed with microsomes. Calculations of \( f_{u,inc} \) were performed in three independent experiments with four replicates per group. \( IC_{50,u} \) and \( K_{i,u} \) values were calculated using following equations:

\[
IC_{50,u} = f_{u,inc} \times IC_{50} \quad \text{and} \quad K_{i,u} = f_{u,inc} \times K_i
\]

**Prediction of potential in vivo DDIs by static modelling**

To predict the risk of a clinical DDI, basic static models of reversible inhibition were utilized following FDA recommended guidelines. The predicted hepatic and systemic area under the curve ratios (\( AUCR_{hep} \) and \( AUCR_{sys} \), respectively) were calculated to determine the overall effect of cannabinoids and their metabolites on a given probe substrate. The basic static model is described by the following equations:

\[
AUCR_{hep} = 1 + \frac{l_{hep,u}}{K_{i,u}}
\]

where \( l_{hep,u} = f_{u,p} \times \left( C_{max} + \frac{F_u \times K_u \times \text{Dose}}{Q_{hep}/R_B} \right) \)
AUCR\textsubscript{sys} = 1 + \frac{l_{\text{sys}}}{K_{i,u}} \tag{3}

where \( l_{\text{sys}} = C_{\text{max},u} \) \tag{4}

AUCR\textsubscript{hep} is calculated using equation 1, where \( l_{\text{hep},u} \) is the unbound maximum hepatic inlet concentration and the \( K_{i,u} \) is calculated for each inhibitor as described above.

The \( l_{\text{hep},u} \) is calculated using equation 2, where \( f_{u,p} \) is the unbound concentration of drug in plasma and was set at 0.03 based on the plasma protein binding of THC (Garrett and Hunt, 1974) which was suggested to be accurate for 11-OH-THC, CBD, CBN as well as THC-COO-Gluc in previous studies (Skopp et al., 2002). \( C_{\text{max}} \) is the maximum concentration of total drug in plasma (parameters described below), \( F_a \) is the fraction of dose absorbed from the gut lumen [set to 1 as recommended by the FDA (Food and Drug Administration, 2020)], \( K_a \) is the rate of intestinal absorption time [set to 0.02; (Cox et al., 2019)], \( R_p \) is the ratio of drug concentration in blood (\( C_B \)) to drug concentration in plasma [set to 0.4 as recommended by Schwilke et al. (Schwilke et al., 2009)], and \( Q_{\text{hep}} \) is the hepatic blood flow = 1500 mL/min (Food and Drug Administration, 2020). For THC, the \( C_{\text{max}} \) was set to 65 nM for a 40 mg oral dose of THC and 254 nM for a 54 mg inhaled dose of THC (Schwope et al., 2011; Cox et al., 2019). For 11-OH-THC, the \( C_{\text{max}} \) was set to 69.7 nM for a 20 mg oral dose of THC and 50 nM for a 46 mg inhaled dose of THC (Ménétrey et al., 2005; Hunault et al., 2008). For THC-COO-Gluc, the \( C_{\text{max}} \) was set to 405 nM for an oral dose of 50 mg of THC and to 385 nM for a 54 mg inhaled dose of THC (Spindle et al., 2020). For CBD, the \( C_{\text{max}} \) was set to 703 nM for an oral dose of 800 mg of CBD and to 10.3 nM for a 20 mg inhaled dose of CBD (Manini et al., 2015; Cox et al., 2019).

The AUCR\textsubscript{sys} is calculated using equation 3, where \( l_{\text{sys}} \) is equal to \( C_{\text{max},u} \) which is the maximum concentration of total unbound drug in plasma (\( C_{\text{max}}/f_{u,p} \)).
An $\text{AUCR}_{\text{hep}} \geq 1.25$ or an $\text{AUCR}_{\text{sys}} \geq 1.02$ indicates a strong pre-systemic hepatic or systemic drug interaction potential.
Results

Prescreening of THC, 11-OH-THC, THC-COOH, THC-COO-Gluc, CBD, and CBN as potential CYP450 inhibitors showed that 10 µM THC decreased the relative activity of several CYP isoforms to approximately 50%, including CYP1A2 (35%), CYP2B6 (50%), CYP2C9 (48%), CYP2D6 (48%), and CYP2C19 (51%), as compared to reactions without added cannabinoid (Figure 2, panel A). Similar levels of inhibition were observed for 11-THC-OH against CYP2B6, CYP2C9, and CYP2D6, with 10 µM 11-THC-OH resulting in relative activity levels between 27-48% for the three enzymes (Figure 2, panel B). While no significant inhibition was observed using up to 10 µM THC-COOH against any of the CYP enzymes tested (Figure 2, panel C), 10 µM THC-COO-Gluc resulted in 25-49% relative activity for CYP2B6, CYP2C9, and CYP2D6 (Figure 2, panel D). In addition, decreases in the relative activity to less than 50% was observed for 10 µM CBD against several CYP enzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4), and for 1 µM CBD against CYP1A2 (45%), CYP2B6 (50%), CYP2E1 (49%), and CYP3A4 (47%; Figure 2, panel E). Similar decreases in relative activity were observed for CBN against CYP2B6, CYP2C9, and CYP2E1, with 75%, 55%, and 80% decreases in activity observed for 10 µM CBN against all three enzymes, and a 77% decrease observed for 1 µM CBN against CYP2E1 (Figure 2, panel F). Initial screening results were validated in assays using commercially prepared pooled HLM (data not shown).

Using microsomes from both specific CYP450-overexpressing HEK293 cell lines (rCYP) and HLM, the inhibitory effects of THC, 11-OH-THC, THC-COOH, THC-COO-Gluc, CBD, and CBN were extended to establish ICₕ₀ values for each cannabinoid against the CYP enzymes shown to be inhibited in the rCYP screening assays (described above). The unbound fraction (fᵤ,inc) of THC, 11-OH-THC, THC-COO-Gluc, CBD and CBN in incubation mixtures (fᵤ,inc) was calculated as 0.051 ± 0.033 and 0.043 ± 0.012, 0.094 ± 0.014 and 0.078 ± 0.042, 0.43 ± 0.071
and 0.45 ± 0.061, 0.098 ± 0.023 and 0.062 ± 0.011, and 0.052 ± 0.081 and 0.030 ± 0.052 in mixtures containing HLM or microsomes from HEK293 cells, respectively. The range in \( f_{u,inc} \) was from 0.030 (CBN) to 0.45 (THC-COO-Gluc) for HEK293 microsomes and 0.051 (THC) to 0.43 (THC-COO-Gluc) for HLM. The values for HLM were similar to those obtained for HEK293 microsomes for all cannabinoids tested. Interestingly, THC-COO-Gluc exhibited a \( f_{u,inc} \) that was approximately 10-fold higher than the other cannabinoids, indicating less adsorption to the components of the incubation mixture.

CBD exhibited strong inhibition against every CYP450 tested, with a range in \( IC_{50,u} \) values of 0.037 – 0.22 µM, with the strongest inhibition observed against rCYP2E1 microsomes (\( IC_{50,u} = 0.037 ± 0.0081 \) µM; Table 1). Additionally, THC exhibited strong inhibition against rCYP1A2, rCYP2B6, rCYP2C9, rCYP2C19 and rCYP2D6 microsomes (\( IC_{50,u} \) values of 0.12 µM ± 0.052 µM, 0.43 ± 0.28 µM, 0.19 µM ± 0.13 µM, 0.15 ± 0.030 µM and 0.47 µM ± 0.077 µM, respectively). The THC metabolites, 11-OH-THC and THC-COO-Gluc both exhibited slightly stronger inhibition against rCYP2D6 (\( IC_{50,u} \) values of 0.34 ± 0.12 µM and 3.5 ± 0.72 µM, respectively) and rCYP2B6 (\( IC_{50,u} \) values of 0.55 ± 0.26 µM and 2.5 ± 0.72 µM, respectively) than THC, while exhibiting similar or less effective inhibition against rCYP2C9 microsomes (\( IC_{50,u} \) values of 0.30 ± 0.086 µM and 6.8 ± 2.0 µM, respectively). CBN exhibited strong inhibition against rCYP2B6 (\( IC_{50,u} = 0.63 ± 0.26 \) µM), rCYP2C9 (\( IC_{50,u} = 0.42 ± 0.13 \) µM), and rCYP2E1 (\( IC_{50,u} = 0.28 ± 0.030 \) µM) microsomes. Similar \( IC_{50} \) values were obtained for HLM using specific probe substrates for all CYP450s examined (Table 1).

To confirm the high level of inhibitory activity observed with cannabinoids against CYP2B6, CYP2C9 and CYP2D6, \( IC_{50} \) determinations were also performed for three additional probe substrates. Strong inhibition of activity against efavirenz, bufuralol and S-warfarin in microsomes from rCYP2B6, rCYP2D6 and rCYP2C9 cell lines, respectively, was observed with THC, 11-OH-THC, THC-COO-Gluc, CBD, and CBN (Supplemental Table 2). Consistent with
that observed for CBN with dextromethorphan as a probe substrate for CYP2D6, no inhibition was observed with this cannabinoid for bufuralol. These data suggest that the inhibition observed with these cannabinoids against these three enzymes is seen across multiple substrates.

**IC**<sub>50</sub>-shift assays were performed for microsomes from each CYP450-overexpressing cell line with the goal of evaluating the time-dependent inhibition (TDI) potencies of cannabinoid metabolites (Table 2). Using a value of 1.5 as the cutoff, none of the cannabinoids tested demonstrated TDI with the possible exception of CBD for CYP2D6, with an exhibited shift of 1.5.

Additional experiments to determine **K**<sub>i,u</sub> values were performed to further understand the strength and type of inhibition interactions occurring between the cannabinoids and the CYP enzymes. As shown in Lineweaver Burk plots, the CYP2B6-catalyzed 4-hydroxylation of bupropion in microsomes from the rCYP2B6 overexpressing cell line was shown to be inhibited in a competitive manner by the THC metabolites 11-OH-THC and THC-COO-Gluc (Figure 3) and the cannabinoids THC, CBD, and CBN (Supplemental Figure 2), with **K**<sub>i,u</sub> values similar for all inhibitors ranging from 0.021 ± 0.0061 µM for CBD against CYP2E1 to 0.30 ± 0.057 µM for CBN against CYP2C9 (Table 3). Slightly higher **K**<sub>i,u</sub> values were observed for inhibition in HLM, ranging from 0.058 ± 0.023 µM for CBD against CYP2E1 to 0.99 ± 0.68 µM for CBN against CYP2C9 (Table 3).

**K**<sub>i,u</sub> values for the inhibition of rCYP2C9 were determined by monitoring the hydroxylation of the CYP2C9 probe substrate, diclofenac. Lineweaver-Burk plots for the inhibition of rCYP2C9 (Figure 3 and Supplemental Figure 2) indicated a competitive type of inhibition for all cannabinoids tested in rCYP2C9-overexpressing cell microsomes, with **K**<sub>i,u</sub> values ranging from 0.057 ± 0.044 µM for 11-OH-THC to 2.1 ± 0.081 µM for THC-COO-Gluc (Table 3). The inhibition of diclofenac hydroxylation in HLM was similar, ranging from 0.17 ± 0.046 µM for THC to 3.4 ± 0.28 µM for THC-COO-Gluc. Slightly higher **K**<sub>i,u</sub> values were observed for inhibition in HLM, with
THC and THC-COO-Gluc exhibiting mixed-type inhibition, while 11-OH-THC, CBD, and CBN exhibited competitive inhibition (Table 3).

For CYP2D6, \( K_{i,u} \) values were determined by examining the O-demethylation of dextromethorphan to dextrorphan. Lineweaver Burk plots for the inhibition of CYP2D6 (Figure 3 and Supplemental Figure 2) suggested a competitive type of inhibition for all inhibitors for both rCYP2D6 microsomes and HLM. The \( K_{i,u} \) values for THC, THC-OH, THC-COO-Gluc, and CBD against rCYP2D6 were 0.11 ± 0.015 \( \mu \)M, 0.15 ± 0.067 \( \mu \)M, 2.3 ± 0.54 \( \mu \)M, and 0.074 ± 0.048 \( \mu \)M, respectively; similar \( K_{i,u} \) values were observed for dextromethorphan-O-demethylation activity for the four cannabinoids in HLM (Table 3).

In addition to CYPs 2B6, 2C9, and 2D6, THC also inhibited CYP1A2-catalyzed phenacetin O-deethylation in rCYP1A2 microsomes, with a \( K_{i,u} \) value of 0.090 ± 0.027 \( \mu \)M; a similar level of inhibition (\( K_{i,u} = 0.12 ± 0.074 \) \( \mu \)M) was also observed for CBD. Inhibition by THC was determined to be competitive, while inhibition by CBD was mixed (Table 3). Highly similar \( K_{i,u} \) values were observed for the two cannabinoids in HLM (Table 3).

Among the cannabinoid compounds tested, only CBD inhibited CYP3A4-catalyzed midazolam 1'-hydroxylation. This inhibition was competitive, with \( K_{i,u} \) values of 0.093 ± 0.037 \( \mu \)M and 0.21 ± 0.11 \( \mu \)M in rCYP3A4 microsomes and HLM, respectively. CYP2C19-catalyzed omeprazole 5'-hydroxylation activity was inhibited by THC with a mixed-type inhibition mechanism for rCYP2C19 microsomes (\( K_{i,u} = 0.056 ± 0.018 \) \( \mu \)M) and HLM (\( K_{i,u} = 0.21 ± 0.082 \) \( \mu \)M), and by CBD, with a competitive mechanism in rCYP2C19 microsomes and a mixed-type in HLM (\( K_{i,u} = 0.050 ± 0.0057 \) \( \mu \)M and 0.092 ± 0.0062 \( \mu \)M, respectively). CYP2E1-catalyzed chlorzoxazone 6-hydroxylation activity was competitively inhibited by CBD and CBN, with \( K_{i,u} \) values for rCYP2E1 of 0.021 ± 0.0061 \( \mu \)M and 0.063 ± 0.029 \( \mu \)M, respectively; the \( K_{i,u} \) values for the inhibition of chlorzoxazone 6-hydroxylation activity in HLM were again similar to that
observed for rCYP microsomes, with $K_{i,u}$ values of $0.058 \pm 0.023 \, \mu M$ and $0.17 \pm 0.047 \, \mu M$ for CBD and CBN, respectively (Table 3).

A basic mechanistic static model populated with $K_{i,u}$ data from the present study predicts $AUCR_{hep}$ and $AUCR_{sys}$ with a strong potential for pharmacokinetic interactions between CBD (both oral and inhaled) and CYP1A2, CYP3A4, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP2E1 (Table 4). For oral dosing of THC, the potential for pharmacokinetic interactions was observed for CYP1A2, CYP2C9, CYP2C19 and CYP2D6, while for inhaled THC there is a potential for pharmacokinetic interactions with CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP2D6. 11-OH-THC showed potential for pharmacokinetic interactions with CYP2B6, CYP2C9 and CYP2D6 for oral and inhaled dosing. THC-COO-Gluc showed potential for pharmacokinetic interactions with CYP2B6, CYP2C9 and CYP2D6 for both oral and inhaled dosing of THC.
Discussion

In the present study, the inhibitory effects of major cannabinoids and THC metabolites on major hepatic CYP450s were investigated. Consistent with previous studies (Jiang et al., 2011; Yamaori et al., 2011a; Yamaori et al., 2011b; Yamaori et al., 2011c; Jiang et al., 2013; Cox et al., 2019), THC demonstrated reversible inhibition of CYPs 1A2, 2B6, 2C9, 2C19, and 2D6 activity; CBD demonstrated reversible inhibition of CYPs 1A2, 3A4, 2B6, 2C9, 2C19, and 2D6; and CBN demonstrated reversible inhibition of CYPs 2B6 and 2C9. While not examined in previous studies, CYP2E1 was also inhibited by the major cannabinoids, with both CBD and CBN demonstrating strong, competitive inhibition of this CYP. In ranking the magnitude of inhibition observed in CYP450-overexpressing cell lines, inhibition by THC was shown to be highest for CYP2C19, followed by 2C9 > 1A2 > 2D6 > 2B6; inhibition by CBD was highest for CYP2E1, followed by 2C19 > 2B6 > 2D6 > 3A4 ~2C9 > 1A2; and inhibition by CBN was also highest for CYP2E1, followed by 2B6 > 2C9.

Prior to the present analysis, a comprehensive inhibition study of hepatic CYP enzymes by all major THC metabolites (11-OH-THC, THC-COOH, and THC-COO-Gluc) had not been previously performed. In the present study, 11-OH-THC and THC-COO-Gluc competitively inhibited CYP2B6, CYP2C9, and CYP2D6 activity, with no inhibition of any CYP enzyme observed with THC-COOH. Inhibition by 11-OH-THC was shown to be highest for CYP2C9, followed by CYP2D6 and then CYP2B6, while inhibition by THC-COO-Gluc was highest for CYP2B6, followed by CYP2C9, and then CYP2D6. In contrast to THC and its active metabolite THC-OH, THC-COOH and THC-COO-Gluc
are present in the plasma at constant and relatively high levels and remain stable in the bloodstream over many days. THC-COOH and THC-COO-Gluc levels are approximately 2.0- and 7.6-fold higher, respectively, than THC after administration by cannabis inhalation, whereas after oral administration, 11-OH-THC and COOH-THC are 2.5- and 40-fold higher than the levels of THC (THC-COO-Gluc levels have not been tested in plasma after oral administration) (Nadulski et al., 2005; Schwope et al., 2011; Bansal et al., 2020). These data suggest that 11-OH-THC and THC-COO-Gluc potentially play an important role in the inhibition of major hepatic CYP enzymes upon cannabis consumption.

All the cannabinoids and metabolites tested in the present study were reversible inhibitors of CYP2B6 bupropion hydroxylation activity. A strong inhibition was observed by the cannabinoid metabolites 11-THC-OH and THC-COO-Gluc, acting in a competitive and reversible manner. In addition to the fact that CYP2B6 is responsible for the metabolism of numerous drugs and other agents, including bupropion, efavirenz, cyclophosphamide, ifosamide, pethidine, artemisinin, propofol, ketamine, and selegiline, current estimates indicate that CYP2B6 accounts for 2%–10% of total hepatic CYP content (Code et al., 1997; Hanna et al., 2000; Hesse et al., 2000; Hedrich et al., 2016). Two of the most well-studied and better-understood drugs with respect to CYP2B6 metabolism are the anticancer drug cyclophosphamide and the anti-HIV medication efavirenz. Both of these widely used drugs have very narrow therapeutic indices, and variations in CYP2B6 expression along with enzyme inhibition lead to significantly altered drug plasma concentrations and associated toxicities (Hedrich et al., 2016). In recent years, cannabinoids have been extensively used for the treatment of various
cancers to alleviate the side effects from anticancer agents such as cyclophosphamide, which has been used as a treatment for cancer and autoimmune disorders for more than half a century. In a clinical study, cyclophosphamide did not demonstrate an improvement in nausea and vomiting when administered in combination with cannabis or oral THC as compared with placebo, which might be explained by the inhibition of CYP2B6 activity by THC and its metabolites and the subsequent increase of in vivo AUC of cyclophosphamide, which is primarily metabolized by CYP2B6 (Abrams, 2016).

Additionally, there is growing recognition that individuals with HIV report greater cannabis use than the general population. Efavirenz is reported to carry a risk of side effects that includes adverse neuropsychiatric complications such as depression, anxiety, hallucinations, and delusions. Several studies showed that the combination of EFV and THC might result in stronger hallucinating power and increased depression, which potentially could be caused by the inhibitory effects of cannabinoids and their metabolites (Mthembi et al., 2018). In addition, bupropion is an antidepressant that is often utilized as an aid to quit smoking and is almost exclusively metabolized by CYP2B6 (Hesse et al., 2000). Bupropion has been shown to cause increased adverse effects (irritability, restlessness, insomnia increased) in a clinical study when participants actively smoked cannabis (Haney et al., 2001). These increased adverse effects might also be caused by the inhibitory effects of cannabinoids on CYP2B6 when co-administered with bupropion. Lastly, ketamine is a medical-grade anesthetic that can be swallowed, snorted, injected, or smoked, often together with cannabis or tobacco. Although there are no studies exploring how ketamine and cannabis interact, users tend
to report that cannabis increases the ketamine high and can, in some instances, exacerbate effects like drowsiness and dizziness (Garcia-Romeu et al., 2016).

The CYP2C9 hydroxylation of diclofenac was also strongly inhibited by the cannabinoid metabolites 11-THC-OH and THC-COO-Gluc in a reversible manner, with a competitive type in the rCYP and mixed in HLM. Previous studies have also found potent inhibition of CYP2C9 by THC, CBD, and 11-THC-OH (Bansal et al., 2020). CYP2C9 is one of the most abundant CYP enzymes in the liver (about 20% of the hepatic total CYP content) (Ghodke-Puranik and Lamba, 2017). It metabolizes several important drugs, including anti-cancer agents, nonsteroidal anti-inflammatory agents, selective cyclooxygenase-2 inhibitors, antibiotics, anti-diabetics, anti-epileptics, anti-hypertensives, anti-coagulants, and anti-hyperlipidemias (Ghodke-Puranik and Lamba, 2017). Drug-drug interactions have been shown to arise when a CYP2C9 inhibitor is added to a therapeutic regime, including low therapeutic index drugs like (S)-warfarin, tolbutamide, or phenytoin. In these cases, patients can risk life-threatening bleeding episodes, hypoglycemia, and neurotoxicity as a result of the diminished CYP2C9 enzyme activity. These in vitro predictions are largely consistent with many clinical CBD- or THC-drug interactions reported to date. In clinical studies, an increased anticoagulant effect of warfarin was previously observed in smokers of cannabis, potentially due to inhibition of CYP2C9-mediated warfarin metabolism by cannabinoids and THC metabolites (Yamreudeewong et al., 2009). In addition, a case report showed that phenytoin caused severe adverse effects when co-administered with cannabis (Jessen, 2004).
THC, 11-OH-THC, THC-COO-Gluc, and CBD also strongly inhibited the dextromethorphan-O-demethylase activity of CYP2D6 in a reversible and competitive manner. Though CYP2D6 comprises a relatively small percentage (2% to 6%) of the total CYP450 protein in the liver, it is involved in the metabolism of 25% of the most commonly prescribed drugs (e.g., antidepressants, antipsychotics, opioids, and beta blockers) (Shannon, 2007). While there are no reports on in vivo drug interactions between cannabinoids and CYP2D6 substrates, the results from the present study can potentially explain the in vivo mechanism for increased adverse effects or potency of CYP2D6-metabolized agents. For example, dextromethorphan is a widely used antitussive agent metabolized by CYP2D6 into an active metabolite, dextrorphan. Using dextromethorphan together with cannabis has been shown to increase side effects such as dizziness, drowsiness, confusion, and difficulty concentrating (Ziaee et al., 2005). In addition, the widely used anticancer drug and CYP2D6 substrate, tamoxifen, showed decreased tamoxifen metabolism in vivo and the level of CYP2D6-mediated active metabolite endoxifen decreased in plasma in subjects also taking cannabinoids (Parihar et al., 2020).

For CYP1A2 and CYP2C19, a mixed-type inhibition was observed for CBD and THC, respectively, in both rCYPs and HLM, suggesting that, in contrast to the competitive type inhibition observed for most of the cannabinoids and THC metabolites analyzed in this study, THC and CBD are not interacting with CYP1A2 and CYP2C19 in a similar fashion. In addition, CYP2C9 and CYP2C19 showed different types of inhibition when analyzing their corresponding rCYP microsomes versus HLM, with THC, THC-COO-Gluc and CBD all exhibiting competitive inhibition in the rCYP and mixed
inhibition in HLM, possibly due to a confounding effect of the presence of multiple CYPs within HLM.

Though cannabis can be consumed through oral dosing, smoking cannabis is still the most common way of consumption. These differences become important when analyzing metabolite levels, as the major THC metabolites will differ in plasma concentration based on the route of administration. After smoking a cannabis cigarette containing 10 mg THC, the plasma AUCs of THC, 11-OH-THC, and THC-COO-Gluc are 110 µg/L (0.35 µM), 19 µg/L (0.06 µM) and 840 µg/L (1.6 µM), respectively. In contrast, after oral dosing of a consumable containing 10 mg of THC, the AUCs of THC and 11-OH-THC are even higher, at 360 µg/L (1.14 µM) and 14,600 µg/L (28 µM), respectively (Nadulski et al., 2005). THC-COO-Gluc levels were 139 µg/L (0.27 µM) after a controlled oral administration of 51 mg THC (Newmeyer et al., 2016). The daily dosage of cannabis varies widely among users, dependent on such factors as the THC: CBD ratio of the product, cannabis use history, and puff duration. THC is recreationally used at around 30-100 mg per joint or vaporizer, whereas the inhaled dose for medicinal use is lower, at approximately 6-80 mg THC (Bansal et al., 2020). Based on these data, the plasma levels of THC and its metabolites will be at higher or similar levels compared to the $K_i$ values and inhibitory concentrations calculated for the different CYP450 enzymes in the present study. In addition, since cannabinoids are readily distributed in various tissues due to their high lipophilicity, the tissue concentration of THC and its metabolites may be even higher than the plasma concentration.
Unlike that described by Bansal et al. (Bansal et al., 2020), TDI was not observed for CBD for the CYP enzymes tested in the present study with the possible exception of CYP2D6. These differences are likely due to experimental conditions, with the present studies conducted using microsomes from CYP450-overexpressing cell lines with each inhibition assay performed independently using individual probe substrates. In contrast, Bansal et al. performed their assays using a ‘cocktail method’ with multiple probes added into one reaction with HLM as the CYP450 protein source. In addition, while BSA was used in the reaction mixture in the Bansal studies, none was added to the assays within the present study.

In conclusion, cannabinoids and the major THC metabolites were shown to strongly inhibit several CYP enzymes including CYP2B6, CYP2C9, and CYP2D6 in the present study. Most importantly, the most abundant and previously untested THC metabolite in plasma, THC-COO-Gluc, is likely to play a major role in the inhibition of several hepatic CYP enzymes. Further investigations into the nature of inhibition of cannabinoids and their metabolites against specific agents will help to clarify the precise mechanism of in vivo cannabis-drug interactions.
Conflict of interests

None declared.

Acknowledgements

The authors would like to thank Shelby Coates, Keti Bardhi and Dr. Gang Chen for their helpful advice and contributions to the project.

Authorship contributions

Participated in research design: Nasrin, Watson, and Lazarus.

Conducted experiments: Nasrin.

Contributed new reagents or analytic tools: Perez-Paramo (CYP2B6, CYP2C19 and CYP2E1 overexpressing cell lines).

Performed data analysis: Nasrin, Lazarus.

Wrote or contributed to the writing of the manuscript: Nasrin, Watson, and Lazarus.
References


Ménétrey A, Augsburger M, Favrat B, Pin MA, Rothuizen LE, Appenzeller M, Buclin T, Marguin P, and Giroud C (2005) Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC. *J Anal Toxicol* **29:**327-338.


Footnotes

This work was supported by the National Institutes of Health National Institutes of Environmental Health Sciences [Grants R01-ES025460] to P. L, the Health Sciences and Services Authority of Spokane, WA [Grant WSU002292] and funds provided by the State of Washington Initiative Measure No. 502.

Citation of meeting abstracts


Reprint requests: Philip Lazarus, Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202-2131. Email: phil.lazarus@wsu.edu
Figure Legends

Figure 1. Major metabolic pathways and metabolic structures of cannabinoids. A, Metabolic pathways for THC and CBD. B, Structure of cannabinoids and major THC metabolites.

Figure 2. Screening of cannabinoid inhibition of major hepatic CYPs in microsomes from CYP450-overexpressing HEK293 cell lines. Probe substrates were phenacetin for CYP1A2, bupropion for CYP2B6, amodiaquine for CYP2C8, diclofenac for CYP2C9, omeprazole for CYP2C19, dextromethorphan for CYP2B6, chlorzoxazone for CYP2E1, and midazolam for CYP3A4. Incubations were performed using 1 or 10 µM of cannabinoid, with probe concentrations at or close to their known $K_m$ for their corresponding enzyme (see Supplementary Table 1). A, THC; B, 11-OH-THC; C, THC-COOH; D, THC-COO-Gluc; E, CBD; F, CBN. Three individual experiments were performed for each probe substrate. Data are expressed as a percentage of metabolite formation formed in assays with cannabinoid compared to assays without cannabinoids.

Figure 3. Lineweaver-Burk plots for the inhibition of CYP2B6, CYP2C9 and CYP2D6 in microsomes from recombinant CYP450-overexpressing cells by THC metabolites. A, inhibition by 11-OH-THC; B, inhibition by THC-COO-Gluc.
Supplemental Figure 1. Chromatograms of probe metabolites in assays containing microsomes from CYP450-overexpressing cells. The probe metabolite examined is described with the mass transition shown in brackets. The traces for D3- or D6-labeled OH-bupropion, 4-hydroxydiclofenac, and dextromethorphan are shown in red.

Supplementary Figure 2. Lineweaver-Burk plots for the inhibition of CYP450 activity in microsomes from recombinant CYP450-overexpressing cells by cannabinoids. A, inhibition by THC; B, inhibition by CBD; C, inhibition by CBN.
Table 1. IC\textsubscript{50} values of cannabinoids and THC metabolites against major hepatic CYP450 enzymes in microsomes from recombinant CYP450-overexpressing cells or HLM.

<table>
<thead>
<tr>
<th>Probe substrate</th>
<th>Microsomal protein</th>
<th>Microsomal protein</th>
<th>THC</th>
<th>THC</th>
<th>THC</th>
<th>THC</th>
<th>CBD</th>
<th>CBN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IC\textsubscript{50} \textsuperscript{a}</td>
<td>IC\textsubscript{50,u} \textsuperscript{a,b}</td>
<td>IC\textsubscript{50}</td>
<td>IC\textsubscript{50,u}</td>
<td>IC\textsubscript{50}</td>
<td>IC\textsubscript{50,u}</td>
<td>IC\textsubscript{50}</td>
<td>IC\textsubscript{50,u}</td>
</tr>
<tr>
<td>phenacetin</td>
<td>2.7 ± 1.2</td>
<td>0.12 ± 0.052</td>
<td>NA</td>
<td>NA</td>
<td>2.1 ± 0.93</td>
<td>0.13 ± 0.058</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>5.2 ± 2.1</td>
<td>0.27 ± 0.11</td>
<td>NA</td>
<td>NA</td>
<td>6.8 ± 1.5</td>
<td>0.67 ± 0.15</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>midazolam</td>
<td>rCYP3A4</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>3.0 ± 0.52</td>
<td>0.19 ± 0.032</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>HLM</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>4.6 ± 1.3</td>
<td>0.45 ± 0.13</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>bupropion</td>
<td>rCYP2B6</td>
<td>10 ± 6.4</td>
<td>0.43 ± 0.28</td>
<td>7.1 ± 3.3</td>
<td>0.55 ± 0.26</td>
<td>2.1 ± 0.61</td>
<td>0.13 ± 0.038</td>
<td>2.1 ± 0.87</td>
</tr>
<tr>
<td></td>
<td>HLM</td>
<td>19 ± 2.3</td>
<td>0.97 ± 0.12</td>
<td>8.2 ± 3.7</td>
<td>0.77 ± 0.35</td>
<td>2.7 ± 2.4</td>
<td>0.26 ± 0.24</td>
<td>1.7 ± 0.59</td>
</tr>
<tr>
<td>diclofenac</td>
<td>rCYP2C9</td>
<td>4.5 ± 3.0</td>
<td>0.19 ± 0.13</td>
<td>3.8 ± 1.1</td>
<td>0.30 ± 0.086</td>
<td>3.6 ± 1.6</td>
<td>0.22 ± 0.099</td>
<td>1.4 ± 0.44</td>
</tr>
<tr>
<td></td>
<td>HLM</td>
<td>7.2 ± 2.6</td>
<td>0.37 ± 0.13</td>
<td>4.8 ± 2.6</td>
<td>0.45 ± 0.24</td>
<td>4.9 ± 1.6</td>
<td>0.48 ± 0.16</td>
<td>2.9 ± 0.51</td>
</tr>
<tr>
<td>omeprazole</td>
<td>rCYP2C19</td>
<td>3.6 ± 0.70</td>
<td>0.15 ± 0.030</td>
<td>NA</td>
<td>NA</td>
<td>2.5 ± 0.50</td>
<td>0.16 ± 0.031</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>HLM</td>
<td>4.2 ± 1.1</td>
<td>0.21 ± 0.056</td>
<td>NA</td>
<td>NA</td>
<td>3.7 ± 1.5</td>
<td>0.36 ± 0.15</td>
<td>NA</td>
</tr>
<tr>
<td>dextromethorphan</td>
<td>rCYP2D6</td>
<td>11 ± 1.8</td>
<td>0.47 ± 0.077</td>
<td>4.3 ± 1.5</td>
<td>0.34 ± 0.12</td>
<td>7.8 ± 1.6</td>
<td>3.5 ± 0.72</td>
<td>3.1 ± 0.64</td>
</tr>
<tr>
<td></td>
<td>HLM</td>
<td>15 ± 5.3</td>
<td>0.77 ± 0.27</td>
<td>6.5 ± 3.4</td>
<td>0.61 ± 0.32</td>
<td>13 ± 3.6</td>
<td>5.6 ± 1.5</td>
<td>5.3 ± 1.0</td>
</tr>
<tr>
<td>chlorzoxazone</td>
<td>rCYP2E1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.59 ± 0.13</td>
<td>0.037 ± 0.0081</td>
<td>0.92 ± 0.10</td>
<td>0.28 ± 0.030</td>
</tr>
<tr>
<td></td>
<td>HLM</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>1.4 ± 0.25</td>
<td>0.14 ± 0.025</td>
<td>1.1 ± 0.72</td>
<td>0.57 ± 0.37</td>
</tr>
</tbody>
</table>

\textsuperscript{a}Values are the mean ± S.D. in µM for four independent experiments with three replicates per group.

\textsuperscript{b}IC\textsubscript{50,u} values represent IC\textsubscript{50} values after correction for unbound fraction (f\textsubscript{u,inc}) of individual cannabinoids as described in the Methods.

\textsuperscript{c}NA, not analyzed.
Table 2. Effect of preincubation on inhibition of CYP activity by cannabinoids and THC metabolites in microsomes from CYP450-overexpressing cell lines.

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>THC</th>
<th>11-OH-THC</th>
<th>THC-COO-Gluc</th>
<th>CBD</th>
<th>CBN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(-)</td>
<td>(+)×</td>
<td>shift</td>
<td>(-)</td>
<td>(+)</td>
</tr>
<tr>
<td></td>
<td>(+)×</td>
<td>(+)×</td>
<td></td>
<td>(+)</td>
<td>(+)</td>
</tr>
<tr>
<td></td>
<td>(-)</td>
<td>(+)×</td>
<td></td>
<td>(+)</td>
<td>(+)</td>
</tr>
<tr>
<td></td>
<td>(+)×</td>
<td>(+)×</td>
<td></td>
<td>(+)</td>
<td>(+)</td>
</tr>
<tr>
<td>CYP1A2</td>
<td>2.7 ± 1.0 1.8 ± 0.55 1.4 ± 0.12</td>
<td>NA×</td>
<td>2.1 ± 0.25 1.8 ± 0.31 1.2 ± 0.20</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP3A4</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>3.1 ± 1.2 2.0 ± 1.1 1.1 ± 0.077</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2B6</td>
<td>19 ± 5.1 18 ± 5.0 1.1 ± 0.049</td>
<td>7.3 ± 1.0 6.1 ± 1.0 1.2 ± 0.094</td>
<td>5.1 ± 1.6 4.1 ± 1.0 1.4 ± 0.16</td>
<td>1.9 ± 0.66 1.3 ± 0.65 1.3 ± 0.048</td>
<td>2.1 ± 0.83 2.0 ± 0.70 1.1 ± 0.061</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2C9</td>
<td>3.4 ± 2.3 2.3 ± 1.7 1.4 ± 0.17</td>
<td>3.2 ± 0.61 2.2 ± 0.59 1.4 ± 0.18</td>
<td>15 ± 2.4 15 ± 2.7 1.0 ± 0.044</td>
<td>2.2 ± 1.2 1.8 ± 0.85 1.2 ± 0.12</td>
<td>3.0 ± 2.2 2.7 ± 2.1 1.1 ± 0.11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2C19</td>
<td>3.2 ± 2.5 2.5 ± 1.8 1.3 ± 0.13</td>
<td>NA</td>
<td>NA</td>
<td>2.5 ± 1.5 2.3 ± 1.3 1.1 ± 0.074</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2D6</td>
<td>13 ± 0.67 10 ± 0.92 1.3 ± 0.068</td>
<td>2.9 ± 0.86 2.1 ± 0.49 1.3 ± 0.14</td>
<td>8.1 ± 1.1 6.4 ± 2.5 1.4 ± 0.51</td>
<td>2.9 ± 1.1 2.0 ± 0.76 1.5 ± 0.33</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2E1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>1.1 ± 0.66 0.9 ± 0.40 1.2 ± 0.20</td>
<td>0.87 ± 0.15 0.73 ± 0.21 1.2 ± 0.16</td>
</tr>
</tbody>
</table>

a (-), IC50 ± S.D. (µM) value of three experiments with 30 min preincubation of test cannabinoid with enzyme without NADPH.
b (+), IC50 ± S.D. (µM) value of three experiments with 30 min preincubation of test cannabinoid with enzyme and NADPH.
c Shift = (IC50 “minus NADPH”/IC50 “plus NADPH”) ± S.D. of three experiments.
d NA, not analyzed.
Table 3. Summary of $K_i$ values and inhibition type for major cannabinoids and THC metabolites against hepatic CYP450 enzymes.*

<table>
<thead>
<tr>
<th>Microsomal Protein</th>
<th>THC</th>
<th>11-OH-THC</th>
<th>THC-COO-Gluc</th>
<th>CBD</th>
<th>CBN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$K_i$</td>
<td>$K_{iu}$</td>
<td>$T$</td>
<td>$K_i$</td>
<td>$K_{iu}$</td>
</tr>
<tr>
<td>rCYP1A2*</td>
<td>2.1 ± 0.62</td>
<td>0.090 ± 0.027</td>
<td>C</td>
<td>NA*</td>
<td>1.9 ± 1.2</td>
</tr>
<tr>
<td>HLM</td>
<td>2.0 ± 1.1</td>
<td>0.10 ± 0.056</td>
<td>C</td>
<td>NA</td>
<td>2.1 ± 1.1</td>
</tr>
<tr>
<td>rCYP3A4</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>1.5 ± 0.59</td>
<td>0.093 ± 0.057</td>
</tr>
<tr>
<td>HLM</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>2.2 ± 0.45</td>
<td>0.22 ± 0.044</td>
</tr>
<tr>
<td>rCYP2B6</td>
<td>5.7 ± 1.0</td>
<td>0.25 ± 0.043</td>
<td>C</td>
<td>1.1 ± 0.85</td>
<td>0.086 ± 0.066</td>
</tr>
<tr>
<td>HLM</td>
<td>7.5 ± 0.56</td>
<td>0.38 ± 0.029</td>
<td>C</td>
<td>2.8 ± 0.44</td>
<td>0.26 ± 0.041</td>
</tr>
<tr>
<td>rCYP2C9</td>
<td>1.7 ± 0.53</td>
<td>0.073 ± 0.023</td>
<td>C</td>
<td>0.73 ± 0.56</td>
<td>0.057 ± 0.044</td>
</tr>
<tr>
<td>HLM</td>
<td>3.4 ± 0.91</td>
<td>0.17 ± 0.046</td>
<td>M</td>
<td>2.2 ± 0.34</td>
<td>0.21 ± 0.032</td>
</tr>
<tr>
<td>rCYP2C19</td>
<td>1.3 ± 0.42</td>
<td>0.056 ± 0.018</td>
<td>M</td>
<td>NA</td>
<td>0.81 ± 0.092</td>
</tr>
<tr>
<td>HLM</td>
<td>4.1 ± 1.6</td>
<td>0.21 ± 0.082</td>
<td>M</td>
<td>NA</td>
<td>0.94 ± 0.063</td>
</tr>
<tr>
<td>rCYP2D6</td>
<td>2.5 ± 0.35</td>
<td>0.11 ± 0.015</td>
<td>C</td>
<td>1.9 ± 0.86</td>
<td>0.15 ± 0.067</td>
</tr>
<tr>
<td>HLM</td>
<td>5.4 ± 0.58</td>
<td>0.28 ± 0.030</td>
<td>C</td>
<td>3.4 ± 2.5</td>
<td>0.32 ± 0.24</td>
</tr>
<tr>
<td>rCYP2E1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0.34 ± 0.098</td>
<td>0.021 ± 0.061</td>
</tr>
<tr>
<td>HLM</td>
<td>0.59 ± 0.23</td>
<td>0.058 ± 0.023</td>
<td>C</td>
<td>0.33 ± 0.091</td>
<td>0.17 ± 0.047</td>
</tr>
</tbody>
</table>

* Values are expressed as µM; shown are the mean ± SD for 3 independent experiments performed for the inhibition of each CYP450 enzyme by each cannabinoid.

b T, type of inhibition. C, competitive inhibition; M, mixed inhibition.

c The probe substrate used were phenacetin, midazolam, bupropion, diclofenac, omeprazole, dextromethorphan and chlorzoxazone for CYP1A2, CYP3A4, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP2E1, respectively.

d NA, not analyzed.
Table 4. Prediction of CYP mediated clinical drug interaction potential after oral or inhaled dose of THC or CBD.\(^a\)

<table>
<thead>
<tr>
<th>enzyme</th>
<th>THC</th>
<th>11-OH-THC</th>
<th>THC-COO-Gluc</th>
<th>CBD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>oral</td>
<td>inhaled</td>
<td>oral</td>
<td>inhaled</td>
</tr>
<tr>
<td></td>
<td>AUCR(_{hep})</td>
<td>AUCR(_{sys})</td>
<td>AUCR(_{hep})</td>
<td>AUCR(_{sys})</td>
</tr>
<tr>
<td>CYP1A2</td>
<td>1.25</td>
<td>1.02</td>
<td>1.08</td>
<td>NA(^b)</td>
</tr>
<tr>
<td>CYP3A4</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>CYP2B6</td>
<td>1.09</td>
<td>1.01</td>
<td>1.03</td>
<td>1.32</td>
</tr>
<tr>
<td>CYP2C9</td>
<td>1.31</td>
<td>1.03</td>
<td>1.10</td>
<td>1.44</td>
</tr>
<tr>
<td>CYP2C19</td>
<td>1.40</td>
<td>1.03</td>
<td>1.13</td>
<td>NA</td>
</tr>
<tr>
<td>CYP2D6</td>
<td>1.20</td>
<td>1.02</td>
<td>1.07</td>
<td>1.17</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

\(^a\) The AUCR\(_{hep}\) and AUCR\(_{sys}\) were calculated for THC, 11-OH-THC and THC-COO-Gluc based on oral or inhaled dosing of THC; the AUCR\(_{hep}\) and AUCR\(_{sys}\) were calculated for CBD based on oral or inhaled dosing of CBD as described in the Materials and Methods.

\(^b\) NA, not analyzed.
**A**

- Cannabidiol (CBD)
  - CYP2C19
  - CYP3A4
  - 7-hydroxy-cannabidiol
    - CYP3A4
  - 7-carboxy-cannabidiol
    - UGT1A1
    - UGT2B7
    - 7-carboxy-cannabidiol glucuronide

- Cyclization

- Δ⁹-tetrahydrocannabinol (THC)
  - CYP2C9
  - CYP2C19
  - 11-hydroxy-Δ⁹-THC (11-OH-THC)
    - CYP3A4
    - 9,10-alpha epoxy tetrahydrocannabinol
    - 8-hydroxy Δ⁹-THC

- Degradation

- 11-carboxy-Δ⁹-THC (11-COOH-THC)
  - UGT1A1
  - UGT1A3
  - 11-carboxy-Δ⁹-THC-glucuronide (THC-COO-gluc)

- Cannabinol (CBN)

**B**

- THC
- 11-OH-THC
- 11-COOH-THC
- THC-COO-gluc
- CBD
- CBN
Figure 2
Figure 3
Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions

Shamema Nasrin, Christy J.W. Watson, Yadira X Perez-Paramo*, Philip Lazarus

Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.

*Current affiliation: Genentech, Inc., South San Francisco, California, USA 94080
Supplemental Figure Legends

Supplemental Figure 1. Chromatograms of probe metabolites in assays containing microsomes from CYP450-overexpressing cells. The probe metabolite examined is described with the mass transition shown in brackets. The traces for D3- or D6-labeled OH-bupropion, 4-hydroxydiclofenac, and dextrorphan are shown in red.

Supplementary Figure 2. Lineweaver-Burk plots for the inhibition of CYP450 activity in microsomes from recombinant CYP450-overexpressing cells by cannabinoids. A, inhibition by THC; B, inhibition by CBD; C, inhibition by CBN.
Supplemental Figure 1

- Acetaminophen (152 > 110.5)
- OH-bupropion (256 > 139.01)
- OH-bupropion-D6 (262 > 146)
- Desethylamodiaquine (328 > 283.4)
- 4-hydroxydiclofenac (312.10 > 266.16)
- 4-hydroxydiclofenac-D3 (318 > 237)
- 5-hydroxyomeprazole (362 > 214.5)
- Dextrorphan (258.10 > 199.05)
- Dextrophan-D3 (261 > 199.01)
- 6-hydroxychlorzoxazone (184 > 120.04)
- 1-hydroxymidazolam (342.20 > 324.05)
Supplemental Figure 2
**Supplemental Table 1. Conditions used for inhibition assays.**

<table>
<thead>
<tr>
<th>CYP</th>
<th>probe substrate</th>
<th>metabolite</th>
<th>probe inhibitor</th>
<th>[substrate] (μM)</th>
<th>incubation time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A2</td>
<td>phenacetin</td>
<td>acetaminophen</td>
<td>furafylline</td>
<td>10</td>
<td>15</td>
</tr>
<tr>
<td>CYP2B6</td>
<td>bupropion</td>
<td>hydroxybupropion</td>
<td>clopidogrel</td>
<td>100</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>efavirenz</td>
<td>8-hydroxyefavirenz</td>
<td></td>
<td>8</td>
<td>15</td>
</tr>
<tr>
<td>CYP2C8</td>
<td>amodiaquine</td>
<td>desethylamodiaquine</td>
<td>montelukast</td>
<td>2</td>
<td>15</td>
</tr>
<tr>
<td>CYP2C9</td>
<td>diclofenac</td>
<td>4’-hydroxydiclofenac</td>
<td>sulfaphenazole</td>
<td>10</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>S-warfarin</td>
<td>7-hydroxywarfarin</td>
<td></td>
<td>10</td>
<td>15</td>
</tr>
<tr>
<td>CYP2C19</td>
<td>omeprazole</td>
<td>5-hydroxyomeprazole</td>
<td>tranlycypromine</td>
<td>1.0</td>
<td>30</td>
</tr>
<tr>
<td>CYP2D6</td>
<td>dextromethorphan</td>
<td>dextrorphan</td>
<td>quinidine</td>
<td>5</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>bufuralol</td>
<td>1-hydroxybufuralol</td>
<td></td>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td>CYP2E1</td>
<td>chlorzoxazone</td>
<td>6-hydroxychlorzoxazone</td>
<td>chlormethiazole</td>
<td>100</td>
<td>15</td>
</tr>
<tr>
<td>CYP3A4</td>
<td>midazolam</td>
<td>1-hydroxymidazolam</td>
<td>ketoconazole</td>
<td>5</td>
<td>8</td>
</tr>
</tbody>
</table>
Supplemental Table 2. Inhibition of cannabinoids and THC metabolites against additional probe substrates for CYP2B6, CYP2D6, and CYP2C9 using microsomes from recombinant CYP450-overexpressing cells.

<table>
<thead>
<tr>
<th>probe substrate</th>
<th>microsomal protein</th>
<th>THC IC50</th>
<th>THC-COO-Gluc IC50,u</th>
<th>11-OH-THC IC50</th>
<th>THC-COO-Gluc IC50,u</th>
<th>CBD IC50</th>
<th>CBN IC50</th>
<th>CBN IC50,u</th>
</tr>
</thead>
<tbody>
<tr>
<td>efavirenz</td>
<td>rCYP2B6</td>
<td>2.8 ± 0.81</td>
<td>0.14 ± 0.0405</td>
<td>5.1 ± 0.52</td>
<td>0.255 ± 0.026</td>
<td>3.2 ± .92</td>
<td>0.16 ± 0.046</td>
<td>3.2 ± 0.58</td>
</tr>
<tr>
<td>bufuralol</td>
<td>rCYP2D6</td>
<td>5.2 ± 0.85</td>
<td>0.26 ± 0.0425</td>
<td>3.1 ± 0.53</td>
<td>0.155 ± 0.026</td>
<td>7.0 ± 1.1</td>
<td>0.35 ± 0.055</td>
<td>1.5 ± 0.28</td>
</tr>
<tr>
<td>S-warfarin</td>
<td>rCYP2C9</td>
<td>3.1 ± 0.48</td>
<td>0.15 ± 0.024</td>
<td>2.8 ± .35</td>
<td>0.14 ± 0.018</td>
<td>7.2 ± .42</td>
<td>0.36 ± 0.021</td>
<td>1.8 ± .21</td>
</tr>
</tbody>
</table>

* NA, not analyzed.